Emphyclear steroidal nasal spray - Emphycorp
Alternative Names: 70% LOWER STEROID COPD SPRAY®; EMPHYCLEARLatest Information Update: 15 Feb 2022
Price :
$50 *
At a glance
- Originator Emphycorp
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease; Unspecified
- Discontinued Asthma
Most Recent Events
- 15 Feb 2022 Discontinued - Clinical-Phase-Unknown for Asthma in USA (PO) (Emphycorp pipeline, February 2022)
- 15 Feb 2022 Discontinued - Phase-III for Asthma in China (PO) (Emphycorp pipeline, February 2022)
- 15 Feb 2022 No development reported - Phase-III for Chronic obstructive pulmonary disease in China (PO) (Emphycorp pipeline, February 2022)